Veeva Systems (NYSE:VEEV) versus Evaxion A/S (NASDAQ:EVAX) Critical Comparison

Veeva Systems (NYSE:VEEV) and Evaxion A/S (NASDAQ:EVAX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Insider and Institutional Ownership

88.2% of Veeva Systems shares are owned by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are owned by institutional investors. 10.3% of Veeva Systems shares are owned by company insiders. Comparatively, 41.6% of Evaxion A/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Veeva Systems and Evaxion A/S, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veeva Systems	2	7	16	0	2.56
Evaxion A/S	1	0	2	0	2.33

Veeva Systems currently has a consensus target price of $303.67, suggesting a potential upside of 2.43%. Evaxion A/S has a consensus target price of $11.00, suggesting a potential upside of 102.58%. Given Evaxion A/S’s higher possible upside, analysts plainly believe Evaxion A/S is more favorable than Veeva Systems.

Profitability

This table compares Veeva Systems and Evaxion A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Veeva Systems	27.29%	13.72%	11.23%
Evaxion A/S	N/A	-319.52%	-63.56%

Valuation and Earnings

This table compares Veeva Systems and Evaxion A/S”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veeva Systems	$2.75 billion	17.69	$714.14 million	$4.87	60.88
Evaxion A/S	$3.34 million	2.28	-$10.57 million	($1.32)	-4.11

Veeva Systems has higher revenue and earnings than Evaxion A/S. Evaxion A/S is trading at a lower price-to-earnings ratio than Veeva Systems, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Veeva Systems has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Comparatively, Evaxion A/S has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500.

Summary

Veeva Systems beats Evaxion A/S on 12 of the 14 factors compared between the two stocks.

About Veeva Systems

Veeva Systems Inc. provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. The company also provides Veeva Development Cloud, a suite of applications for the clinical, regulatory, quality, and safety functions, including Veeva Vault Clinical, Veeva Vault RIM, Veeva Vault Safety, and Veeva Vault Quality; Veeva QualityOne, a quality and document management, and training solution; Veeva RegulatoryOne, a solution that helps companies to manage regulatory submission content; and Veeva Claims addresses the end-to-end product and marketing claims management process. In addition, it offers professional and support services, including implementation and deployment planning and project management; requirements analysis, solution design, and configuration; systems environment management and deployment services; services focused on advancing or transforming business and operating processes related to Veeva solutions; data migration and systems integrations technical consulting services; training on its solutions; and ongoing managed services, such as outsourced systems administration. The company was formerly known as Verticals onDemand, Inc. and changed its name to Veeva Systems Inc. in April 2009. Veeva Systems Inc. was incorporated in 2007 and is headquartered in Pleasanton, California.

About Evaxion A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.